A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

900

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

July 27, 2029

Study Completion Date

July 25, 2031

Conditions

Parkinson's Disease

Interventions

DRUG

Prasinezumab

Participants will receive Prasinezumab as an IV Infusion as per the schedule mentioned in the protocol.

DRUG

Placebo

Participants will receive Placebo as an IV Infusion per the schedule mentioned in the protocol

All Listed Sponsors

collaborator

Prothena Biosciences Limited

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY